Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | EP300 | Q09472 | 10/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430724 | 0.93 | KMT2A (0.44) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL12430708 | 0.92 | KMT2A (0.44) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL12510448 | 0.91 | EP300 (0.51) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL14629554 | 0.89 | EP300 (0.52) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL14629657 | 0.88 | MEN1 (0.46) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL14599447 | 0.82 | KMT2A (0.47) | MEN1KMT2AEP300KAT8ALDH1A1 | |
| SCHEMBL12104760 | 0.82 | ALDH1A1 (0.47) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL14599446 | 0.80 | EP300 (0.43) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL12104815 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AEP300KAT8RAB9A | |
| SCHEMBL1303696 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AEP300KAT8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977366-B2 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20070021448-A1 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021448-A1 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | MPO, MMP8, SERPINB1 | MEN1 4710/4885KMT2A 4421/4885EP300 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.